<DOC>
	<DOC>NCT01169311</DOC>
	<brief_summary>Trial Objectives The primary objectives of this clinical trial are to estimate the Covidien EEAâ„¢ Hemorrhoid and Prolapse Stapling Set: overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.</brief_summary>
	<brief_title>Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure</brief_title>
	<detailed_description />
	<mesh_term>Prolapse</mesh_term>
	<mesh_term>Hemorrhoids</mesh_term>
	<criteria>Able to understand and sign Informed Consent Form The participant must be 1880 years of age. The participant has (symptomatic) Grade 24 Hemorrhoids and is eligible for stapled hemorrhoidopexy. The procedure is needed as revision hemorrhoid surgery. The participant is pregnant. The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date. The participant is unable or unwilling to comply with the study requirements, followup schedule. The participant has a history of drug or alcohol abuse. The participant has a history of venous thrombosis or pulmonary embolism. The participant has a history of coagulopathy. The participant is taking aspirin, anticoagulation and/or anti platelet therapies (e.g.: Warfarin, Levonox) within the last 7 days prior to the planned surgery date The participant has a history of fecal incontinence. The participant has comorbidities which, in the opinion of the investigator, will not be appropriate for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Hemorrhoids</keyword>
	<keyword>Hemorrhoid</keyword>
	<keyword>grade II, III, IV</keyword>
</DOC>